Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2017 | Pages:
54 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Pipeline Review, H1 2017 Summary According to the recently published report 'GTPase KRas - Pipeline Review, H1 2017'; GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) pipeline Target constitutes close to 23 molecules. Out of which approximately 18 molecules are developed by companies and remaining by the universities/institutes. GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - KRAS is a GTPase encoded by the KRAS gene. It plays an important role in the regulation of cell proliferation, promoting oncogenic events by inducing transcriptional silencing of tumor suppressor genes (TSGs) in colorectal cancer (CRC) cells in a ZNF304-dependent manner. The report 'GTPase KRas - Pipeline Review, H1 2017' outlays comprehensive information on the GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities. It also reviewsalso reviews key players involved in GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Preclinical and Discovery stages are 9 and 9 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Non-Small Cell Lung Cancer, Lung Cancer, Pancreatic Cancer, Colon Cancer, Colorectal Cancer, Small-Cell Lung Cancer and Solid Tumor. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - The report reviews GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics and enlists all their major and minor projects - The report assesses GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Overview GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Companies Involved in Therapeutics Development AstraZeneca Plc Aurigene Discovery Technologies Ltd Boehringer Ingelheim GmbH Critical Outcome Technologies Inc Horizon Discovery Group Plc Mirati Therapeutics Inc Nuevolution AB PeptiDream Inc Takeda Pharmaceutical Company Ltd Tosk Inc Warp Drive Bio Inc GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Drug Profiles Antibody to Inhibit KRAS for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress ARS-853 - Drug Profile Product Description Mechanism Of Action R&D Progress AZD-4785 - Drug Profile Product Description Mechanism Of Action R&D Progress COTI-219 - Drug Profile Product Description Mechanism Of Action R&D Progress HD-001 - Drug Profile Product Description Mechanism Of Action R&D Progress KRpep-2d - Drug Profile Product Description Mechanism Of Action R&D Progress MM-41 - Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibody to Inhibit KRAS for Pancreatic Cancer - Drug Profile Product Description Mechanism Of Action R&D Progress Oligonucleotide to Inhibit KRAS for Lung Cancer and Colon Cancer - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit K-RAS for Non-Small Cell Lung Cancer - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit KRAS for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit KRAS for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules 1 to Inhibit K-Ras for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules 2 to Inhibit K-Ras for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules 3 to Inhibit K-Ras for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit K Ras for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit K-Ras for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit KRAS for Non-Small Cell Lung Cancer - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit KRAS for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit KRAS2B for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress SML-8731 - Drug Profile Product Description Mechanism Of Action R&D Progress Synthetic Peptides to Inhibit KRAS for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Vaccine to Target K-RAS for Lung Cancer - Drug Profile Product Description Mechanism Of Action R&D Progress GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Dormant Products GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Product Development Milestones Featured News & Press Releases Dec 16, 2016: Ionis Earns $28 Million from AstraZeneca for a New Drug to Treat Cancer Oct 11, 2016: Critical Outcome Technologies Announces Next Clinical Candidate, COTI-219, Targeting KRAS Jul 29, 2014: Researchers Identify Irreversible Inhibitor for KRAS Gene Mutation May 08, 2013: Sentinel Oncology Achieves Milestone In Horizon Discovery Agreement Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H1 2017 Number of Products under Development by Therapy Areas, H1 2017 Number of Products under Development by Indication, H1 2017 Number of Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 Number of Products under Investigation by Universities/Institutes, H1 2017 Products under Investigation by Universities/Institutes, H1 2017 Number of Products by Stage and Mechanism of Actions, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Pipeline by AstraZeneca Plc, H1 2017 Pipeline by Aurigene Discovery Technologies Ltd, H1 2017 Pipeline by Boehringer Ingelheim GmbH, H1 2017 Pipeline by Critical Outcome Technologies Inc, H1 2017 Pipeline by Horizon Discovery Group Plc, H1 2017 Pipeline by Mirati Therapeutics Inc, H1 2017 Pipeline by Nuevolution AB, H1 2017 Pipeline by PeptiDream Inc, H1 2017 Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017 Pipeline by Tosk Inc, H1 2017 Pipeline by Warp Drive Bio Inc, H1 2017 Dormant Projects, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
